Here's when you can get the FDA-approved, daily pill version of Novo Nordisk's wildly popular GLP-1 drug Wegovy.

The race to treat obesity with powerful new medicines has become one of the defining stories in global healthcare, and Novo ...

Novo Nordisk A/S secures FDA nod for oral Wegovy, expanding obesity treatment options. Click for how oral GLP-1 therapies ...

The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Novo Nordisk (NVO) is a global healthcare company and a prominent player in the diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern insulins and human ...

As Novo Nordisk’s weight-loss pill Wegovy (semaglutide) readies for a launch in the United States early January, it will be a ...

Andrew Rocco, stock strategist at Zacks Investment Research, called Novo's approval "groundbreaking" because the pill would ...

U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The U.S. Food and Drug Administration’s ...

The drugs' high prices, along with spotty insurance coverage, have left them out of reach for many Americans. Read more at ...

Wegovy is one of the new wave medications that in recent years have had a huge impact on people looking to l ose weight.

In a significant development for global health, U.S. regulators have approved an oral version of the Wegovy weight-loss drug, marking the first time this powerful treatment will be available in pill ...

Major stock indexes ended higher for a fourth straight session Tuesday, with the S&P 500 setting a fresh closing record, ...